Inhibitory Effects of Dopamine Receptor D 1 Agonist on Mammary Tumor and Bone Metastasis

Kazumasa Minami, Shengzhi Liu, Yang Liu, Andy Chen, Qiaoqiao Wan, Sungsoo Na, Bai Yan Li, Nariaki Matsuura, Masahiko Koizumi, Yukun Yin, Liangying Gan, Aihua Xu, Jiliang Li, Harikrishna Nakshatri, Hiroki Yokota

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Dopaminergic signaling plays a critical role in the nervous system, but little is known about its potential role in breast cancer and bone metabolism. A screening of ∼1,000 biologically active compounds revealed that a selective agonist of dopamine receptor D1 (DRD1), A77636, inhibited proliferation of 4T1.2 mammary tumor cells as well as MDA-MB-231 breast cancer cells. Herein, we examined the effect of A77636 on bone quality using a mouse model of bone metastasis from mammary tumor. A77636 inhibited migration of cancer cells in a DRD1-dependent fashion and suppressed development of bone-resorbing osteoclasts by downregulating NFATc1 through the elevation of phosphorylation of eIF2α. In the mouse model of bone metastasis, A77636 reduced osteolytic lesions and prevented mechanical weakening of the femur and tibia. Collectively, we expect that dopaminergic signaling might provide a novel therapeutic target for breast cancer and bone metastasis.

Original languageEnglish (US)
Article number45686
JournalScientific Reports
Volume7
DOIs
StatePublished - Apr 4 2017

Fingerprint

A 77636
Dopamine Receptors
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Bone Neoplasms
Dopamine D1 Receptors
Bone Development
Dopamine Agonists
Osteoclasts
Tibia
Femur
Nervous System
Cell Movement
Down-Regulation
Phosphorylation
Neoplasms

ASJC Scopus subject areas

  • General

Cite this

Minami, K., Liu, S., Liu, Y., Chen, A., Wan, Q., Na, S., ... Yokota, H. (2017). Inhibitory Effects of Dopamine Receptor D 1 Agonist on Mammary Tumor and Bone Metastasis. Scientific Reports, 7, [45686]. https://doi.org/10.1038/srep45686

Inhibitory Effects of Dopamine Receptor D 1 Agonist on Mammary Tumor and Bone Metastasis. / Minami, Kazumasa; Liu, Shengzhi; Liu, Yang; Chen, Andy; Wan, Qiaoqiao; Na, Sungsoo; Li, Bai Yan; Matsuura, Nariaki; Koizumi, Masahiko; Yin, Yukun; Gan, Liangying; Xu, Aihua; Li, Jiliang; Nakshatri, Harikrishna; Yokota, Hiroki.

In: Scientific Reports, Vol. 7, 45686, 04.04.2017.

Research output: Contribution to journalArticle

Minami, K, Liu, S, Liu, Y, Chen, A, Wan, Q, Na, S, Li, BY, Matsuura, N, Koizumi, M, Yin, Y, Gan, L, Xu, A, Li, J, Nakshatri, H & Yokota, H 2017, 'Inhibitory Effects of Dopamine Receptor D 1 Agonist on Mammary Tumor and Bone Metastasis', Scientific Reports, vol. 7, 45686. https://doi.org/10.1038/srep45686
Minami, Kazumasa ; Liu, Shengzhi ; Liu, Yang ; Chen, Andy ; Wan, Qiaoqiao ; Na, Sungsoo ; Li, Bai Yan ; Matsuura, Nariaki ; Koizumi, Masahiko ; Yin, Yukun ; Gan, Liangying ; Xu, Aihua ; Li, Jiliang ; Nakshatri, Harikrishna ; Yokota, Hiroki. / Inhibitory Effects of Dopamine Receptor D 1 Agonist on Mammary Tumor and Bone Metastasis. In: Scientific Reports. 2017 ; Vol. 7.
@article{da4e33b75d7541faae8161e00aeafcc3,
title = "Inhibitory Effects of Dopamine Receptor D 1 Agonist on Mammary Tumor and Bone Metastasis",
abstract = "Dopaminergic signaling plays a critical role in the nervous system, but little is known about its potential role in breast cancer and bone metabolism. A screening of ∼1,000 biologically active compounds revealed that a selective agonist of dopamine receptor D1 (DRD1), A77636, inhibited proliferation of 4T1.2 mammary tumor cells as well as MDA-MB-231 breast cancer cells. Herein, we examined the effect of A77636 on bone quality using a mouse model of bone metastasis from mammary tumor. A77636 inhibited migration of cancer cells in a DRD1-dependent fashion and suppressed development of bone-resorbing osteoclasts by downregulating NFATc1 through the elevation of phosphorylation of eIF2α. In the mouse model of bone metastasis, A77636 reduced osteolytic lesions and prevented mechanical weakening of the femur and tibia. Collectively, we expect that dopaminergic signaling might provide a novel therapeutic target for breast cancer and bone metastasis.",
author = "Kazumasa Minami and Shengzhi Liu and Yang Liu and Andy Chen and Qiaoqiao Wan and Sungsoo Na and Li, {Bai Yan} and Nariaki Matsuura and Masahiko Koizumi and Yukun Yin and Liangying Gan and Aihua Xu and Jiliang Li and Harikrishna Nakshatri and Hiroki Yokota",
year = "2017",
month = "4",
day = "4",
doi = "10.1038/srep45686",
language = "English (US)",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Inhibitory Effects of Dopamine Receptor D 1 Agonist on Mammary Tumor and Bone Metastasis

AU - Minami, Kazumasa

AU - Liu, Shengzhi

AU - Liu, Yang

AU - Chen, Andy

AU - Wan, Qiaoqiao

AU - Na, Sungsoo

AU - Li, Bai Yan

AU - Matsuura, Nariaki

AU - Koizumi, Masahiko

AU - Yin, Yukun

AU - Gan, Liangying

AU - Xu, Aihua

AU - Li, Jiliang

AU - Nakshatri, Harikrishna

AU - Yokota, Hiroki

PY - 2017/4/4

Y1 - 2017/4/4

N2 - Dopaminergic signaling plays a critical role in the nervous system, but little is known about its potential role in breast cancer and bone metabolism. A screening of ∼1,000 biologically active compounds revealed that a selective agonist of dopamine receptor D1 (DRD1), A77636, inhibited proliferation of 4T1.2 mammary tumor cells as well as MDA-MB-231 breast cancer cells. Herein, we examined the effect of A77636 on bone quality using a mouse model of bone metastasis from mammary tumor. A77636 inhibited migration of cancer cells in a DRD1-dependent fashion and suppressed development of bone-resorbing osteoclasts by downregulating NFATc1 through the elevation of phosphorylation of eIF2α. In the mouse model of bone metastasis, A77636 reduced osteolytic lesions and prevented mechanical weakening of the femur and tibia. Collectively, we expect that dopaminergic signaling might provide a novel therapeutic target for breast cancer and bone metastasis.

AB - Dopaminergic signaling plays a critical role in the nervous system, but little is known about its potential role in breast cancer and bone metabolism. A screening of ∼1,000 biologically active compounds revealed that a selective agonist of dopamine receptor D1 (DRD1), A77636, inhibited proliferation of 4T1.2 mammary tumor cells as well as MDA-MB-231 breast cancer cells. Herein, we examined the effect of A77636 on bone quality using a mouse model of bone metastasis from mammary tumor. A77636 inhibited migration of cancer cells in a DRD1-dependent fashion and suppressed development of bone-resorbing osteoclasts by downregulating NFATc1 through the elevation of phosphorylation of eIF2α. In the mouse model of bone metastasis, A77636 reduced osteolytic lesions and prevented mechanical weakening of the femur and tibia. Collectively, we expect that dopaminergic signaling might provide a novel therapeutic target for breast cancer and bone metastasis.

UR - http://www.scopus.com/inward/record.url?scp=85017029297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017029297&partnerID=8YFLogxK

U2 - 10.1038/srep45686

DO - 10.1038/srep45686

M3 - Article

C2 - 28374823

AN - SCOPUS:85017029297

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 45686

ER -